A Study of MK0431 in Patients With Type 2 Diabetes (0431-010)

• Status: Completed
• Trial end date: 2006-06-15
• Target enrollment: 0
• Participant gender: All

Summary

A dose-ranging study of MK0431 in patients with type 2 diabetes who have inadequate control of their blood sugar.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Sitagliptin Phosphate

Criteria

Inclusion Criteria:

• Age 21 to 70, You are a man or non-pregnant woman

Exclusion Criteria:

• Have a history of type I diabetes

• You are on a weight loss program with ongoing weight loss or taking weight loss medications

• You have a history of minor surgery

• You have received investigational drugs within 8 weeks of study start

• You have hepatitis B or C